Effects of Sympathicomimetic Agonists on the Disease Course and Mutant Allele Burden in Patients With JAK2-mutated Myeloproliferative Neoplasms. A Multicenter Phase II Trial.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Mirabegron (Primary)
Indications Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera; Thrombocytopenia
Focus Therapeutic Use

28 Dec 2016 Status changed from active, no longer recruiting to completed.
06 Dec 2016 Primary endpoint (Reduction in the burden of mutated alleles of 50% at 24 weeks) has not been met, according to results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com